
BURINOSE
Bumetanide nasal spray for treatment of decompensated hear failure
heart failure
→ symptoms due to reduced pumping function
medication: reduction of symptoms, against fluid and salt retention and better prognosis
decompensated heart failure (decompensatio cordis)
→ (worsening of) symptoms due to salt and water retention, edema formation
​
treatment options:
oral (PO) diuretics: decreased effectiveness (diuretic resistance)
intravenous (IV) diuretics: effective but hospital admission required (high costs, displacement of other care, infections and mental burden)
How can we effectively treat patients at home?
the challenge of treating decompensated heart failure effectively in an outpatient setting when oral diuretics lose effectiveness but IV diuretics require hospitalization.


IP
2021 WO2023285009 (A1) aqueous bumetanide solutions
achieving stable 1mg/50 ul bumetanide solutions with better than oral pk/pd
to be validated july-august 2025
2024 Achieving PK/PD close to IV with nasal application
2025 Achieving PK/PD close to IV with nasal application
​